In the spring of 2020, CRF awarded a grant to AMMA Therapeutics for $304,064, the aim of their study is to develop a once-daily subcutaneous injection of cysteamine bitartate. The project is led by Michael Sekar, PhD, Principal Investigator, and Laura Rita Rega, PhD, Co-Principal Investigator. The project is comprised of three specific Aims. Aim #1, includes formulation development and compatibility, and invitro drug release and syringe injectability which are now complete.
Read about their progress, and the goals for Aim #2, despite the challenges of Covid-19 related disruptions.
Research Progress Report by Michael Sekar, PhD, AMMA Therapeutics, Inc.
